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Abstract 
Background: Niemann-Pick disease type C (NP-C) is a rare, inherited neurodegenerative 
disease of impaired intracellular lipid trafficking. Clinical symptoms are highly 
heterogeneous, including neurological, visceral or psychiatric manifestations. The incidence 
of NP-C is underestimated due to under-recognition or misdiagnosis across a wide range of 
medical fields. New screening and diagnostic methods provide an opportunity to improve 
detection of unrecognized cases in clinical subpopulations associated with a higher risk of 
NP-C. Patients in these at-risk groups ('clinical niches') have symptoms that are potentially 
related to NP-C, but go unrecognized due to other, more prevalent clinical features and lack 
of awareness regarding underlying metabolic causes. 
Methods: Twelve potential clinical niches identified by clinical experts were evaluated based 
on a comprehensive, non-systematic review of literature published to date. Relevant 
publications were identified by targeted literature searches of EMBASE and PubMed using 
key search terms specific to each niche. Articles published in English or other European 
languages up to 2016 were included. 
Findings: Several niches were found to be relevant based on available data: movement 
disorders (early-onset ataxia and dystonia), organic psychosis, early-onset 
cholestasis/(hepato)splenomegaly, cases with relevant antenatal findings or fetal 
abnormalities, and patients affected by family history, consanguinity and endogamy. 
Potentially relevant niches requiring further supportive data included: early-onset cognitive 
decline, frontotemporal dementia, parkinsonism, and chronic inflammatory CNS disease. 
There was relatively weak evidence to suggest amyotrophic lateral sclerosis or progressive 
supranuclear gaze palsy as potential niches. 
Conclusions: Several clinical niches have been identified that harbor patients at increased risk 
of NP-C. 
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Introduction 
Niemann-Pick disease type C (NP-C) is a rare, autosomal recessive, neurodegenerative 
disease caused by mutations in the NPC1 or NPC2 gene that lead to impaired intracellular 
lipid trafficking and excess storage of glycosphingolipids in the brain, liver and other tissues 
[1, 2, 3, 4]. The disease shows a sporadic, panethnic occurrence, affecting between 1:89,000 
and 1:100,000 individuals [5, 6, 7, 8, 9].  
NP-C can be regarded as a role model for other ultra-rare, inherited neurodegenerative 
diseases in a number of ways. Its true incidence is likely underestimated due to under-
recognition and misdiagnosis. Patients with NP-C show extreme clinical heterogeneity in 
their symptom profiles, ages at disease onset, and rates of disease progression [10]. 
Presenting symptoms are often mild and non-specific. Multiple referrals are often required 
between primary care and a wide range of medical specialties including, but not limited to, 
pediatrics, adult neurology, hepatology, hematology and psychiatry. The diagnosis of NP-C 
therefore requires multidisciplinary clinical work-up and, ultimately referral to specialist 
centers with expertise in diagnostic laboratory tests [10, 11]. As a result, many patients 
experience significant delays to diagnosis [7, 8, 12, 13]. 
The core neurological manifestations of NP-C affect movement (e.g., cerebellar ataxia), 
manipulation (e.g., dystonia, dysmetria), speech (dysarthria), and swallowing (dysphagia) 
[11, 14]. Vertical supranuclear gaze palsy (VSGP) is considered highly characteristic, and 
seizures and gelastic cataplexy are also often reported [10, 15]. Visceral symptoms include 
prolonged neonatal jaundice, hepatosplenomegaly, isolated splenomegaly and other 
cholestatic symptoms [10, 16, 17]. A range of psychiatric and behavioral disorders such as 
psychosis, bipolar disorder, developmental delay, and difficulties at school are frequently 
observed [10, 18, 19]. 
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Certain clinical subpopulations are associated with a higher risk of NP-C compared with the 
general population. These 'clinical niches' comprise patients with symptoms that are 
potentially related to NP-C, but which go unrecognized due to other, more prevalent clinical 
features or a lack of emphasis and awareness regarding rare underlying metabolic causes 
(e.g., with complex neurological areas or in psychiatric practice). Targeted screening in 
cohorts of ‘at risk’ patients from such clinical niches may reveal previously unrecognized 
cases of NP-C. Fortunately, improved genetic analysis methods (e.g., next-generation 
sequencing [NGS] and gene panel testing) [9, 20, 21, 22, 23, 24], disease biomarkers (e.g., 
oxysterols, lysosphingolipids and bile acids) [25, 26, 27, 28, 29, 30], and clinical screening 
tools (the NP-C suspicion index [NPC-SI]) [7, 21, 31, 32, 33] are increasingly becoming 
available [21] and provide the opportunity to improve the detection of previously hidden 
cases of NP-C. 
Expert consensus based on published evidence has identified the following potential clinical 
niches for NP-C: movement disorders (early-onset ataxia [EOA] and dystonia); early-onset 
cognitive decline (EOCD); frontotemporal dementia (FTD); parkinsonism; progressive 
supranuclear gaze palsy (PSP); organic psychosis; amyotrophic lateral sclerosis (ALS); 
unclear neuroinflammatory diseases; and hepatosplenomegaly or early-onset cholestasis. A 
family history of NP-C, and patients with antenatal findings or fetal abnormalities related to 
the disease also represent potential niches. 
The following report provides a comprehensive review of all up-to-date information on 
known and putative clinical niches for NP-C. We aim to highlight clinical niches where 
future screening is considered likely to reveal new cases where it might previously have been 
overlooked. 
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Methods 
This non-systematic review of the literature was designed to provide an educational overview 
of current evidence regarding the occurrence of NP-C within 12 potential clinical niches and 
symptoms/methods that can be employed to aid in the identification of NP-C. This review 
was conducted according to a two-step process: 1) identification of potential clinical niches 
by simultaneous expert appraisal of medical fields in which new NP-C cases most often 
present, and specific diseases or disease areas within each relevant medical field that are most 
commonly associated with NP-C; and 2) assessment of identified niches based on 
comprehensive assessment of available, relevant evidence and expert opinion, including 
findings from clinical examination, biomarker evaluations and genetic mutation analyses as 
well as other diagnostic clues (e.g., cranial imaging assessments) observed in NP-C. 
Data were identified by targeted literature searches of EMBASE and PubMed using key 
search terms specific to each niche. Articles published in English or other European 
languages up to 2016 were included. Priority was given to more recent articles. 
Publication types considered suitable for inclusion included systematic reviews and meta-
analyses, randomized controlled trials, epidemiological studies (case–control studies, cohort 
studies) and highly relevant narrative reviews. Given the rare nature of NP-C, case reports 
were also included. Once identified as relevant, all articles were screened for inclusion by in-
depth appraisal of data and other content. References from each included article were also 
assessed for inclusion.  
The relevance of each clinical niche to NP-C was finally appraised, and classified as 'highly 
relevant', 'potentially relevant', 'not relevant' for NP-C based on the frequency of diagnosed 
patients in published reports, expert clinical experience, and other supporting information. 
  8 
 
1. Familial aspects and ancestry 
A family history of NP-C and births from consanguineous parental relationships are widely 
acknowledged as powerful factors in predicting and detecting new cases of NP-C [10, 34, 35, 
36, 37, 38]. In NP-C cohorts from the UK, Europe and Australia, 22–38% of cases were 
related [6, 7, 32]. However, the high proportion of NP-C patients with compound 
heterozygote genotypes makes the study of genotype–phenotype correlations challenging [39, 
40, 41]. NP-C symptoms can vary widely among family members, even in those with 
identical genetic mutations. Family studies in the UK and Czech Republic NP-C cohorts 
identified clinically asymptomatic siblings of patients with both early- and late-onset NP-C 
[6, 42]. 
Regions where consanguineous relationships are common (up to 34% of marriages in some 
regions) tend to be associated with a higher prevalence of autosomal recessive disorders, 
including NP-C [35, 36, 37, 43, 44, 45, 46, 47, 48, 49]. While no published studies have 
directly addressed the influence of endogamy on the occurrence of NP-C, 4/24 patients (17%) 
diagnosed with NP-C were from consanguineous parents in a series of patients evaluated in 
Spain (Pocovi M, personal communication). 
NP-C is a pan-ethnic disease, so endogamy is not considered such a relevant epidemiological 
influence on its occurrence. However, some mutations do tend to be localized to specific 
regions. For instance, regional genetic NP-C isolates are reported from the Greek Islands, the 
Rio Grande Valley in Colorado, and Nova Scotia [40, 50, 51, 52]. The incidence of NP-C in 
the endogamous population of Yarmouth County in Nova Scotia was approximately 1% [53]. 
Sequencing methods for NPC1/NPC2 variants are expected to contribute valuable data on the 
influence of consanguinity and endogamy on NP-C and carrier genotypes in the future [9]. 
Whole-exome sequencing in 143 multiplex consanguineous families associated with 
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autosomal-recessive neurogenesis disorders detected previously reported homozygous NPC2 
mutations in a male index case (i.e., the first patient diagnosed within his family) as well as 
his sibling [54]. This was an intriguing finding as neither of these cases displayed progressive 
neurodegeneration or hepatosplenomegaly typical for their genotype, making it unlikely that 
they would have been detected based on clinical screening methods. To a degree, this finding 
casts some doubt on the variant classification applied. Targeted screening based on direct 
gene sequencing in 510 patients from the Turkish NP-C cohort identified two new patients 
with NP-C among family members of four index cases, and revealed an overall heterozygous 
NPC1/NPC2 mutation frequency of 22.7% (Topçu, personal communication). 
Substantial published data show that family history is the strongest indicator for possible NP-
C cases, even among asymptomatic siblings. Parental genetic studies should be considered in 
index cases and their family members, where appropriate, in order to confirm homozygous 
status and identify/track heterozygote carriers [6, 7, 8, 10].  
Genetic analyses, direct gene sequencing and close monitoring are strongly recommended in 
siblings of patients with confirmed NP-C in order to identify further, as-yet undetected cases 
[8, 10, 11, 55]. 
Biomarker screening, if available, could offer rapid diagnostic information in endogamous 
populations. In addition, if a particular region has a system in place to screen for rare 
metabolic diseases, it would be useful to include common NPC1 variants in the relevant gene 
panel in order to detect new cases and provide genetic counseling. 
 
2. Movement disorders – early-onset ataxia (EOA) 
Cerebellar ataxia is estimated to occur in 85–90% of NP-C patients, but in isolation it is not a 
specific clinical sign of the disease [7, 8, 10, 13, 56]. NP-C is not common among patients 
with pure cerebellar ataxia, or in patients with spastic presentations, and can be discounted in 
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congenital, non-progressive ataxia [13, 56, 57, 58]. Patients with NP-C fall into the diagnostic 
category of 'early-onset ataxia' (EOA) due to ataxia onset below 40 years of age [13, 31, 56, 
59, 60, 61, 62]. Although frequent, EOA may be absent in the initial stages of the disease. 
In NP-C, EOA typically presents as a 'slow ataxia' that is frequently combined with dystonia, 
and in some patients, myoclonus [5, 58, 63]. Gait itself may appear normal at early stages, 
but movements may be slowed and tandem gait may be well performed despite many years of 
disease progression [5]. 
Clinical diagnostic algorithms may aid in differential diagnosis, particularly among patients 
with unexplained ataxia [31, 60, 64, 65, 66, 67]. Symptoms that are observed more frequently 
alongside ataxia in patients with NP-C compared with the general EOA population, which 
can thus serve as highly specific signs include: 1) cognitive decline/psychiatric disturbances; 
2) VSGP; and 3) dystonia (specifically in the hands). A study in 133 EOA patients reported a 
'two out of three rule' that reliably identified patients with unexplained EOA [31]. This simple 
screening method is based on the co-occurrence of EOA with at least two of the three specific 
concomitant NP-C symptoms mentioned above, and provides sensitivity and specificity for 
NP-C (90% in both cases).  
A clinical screening study in 24 patients with cerebellar ataxia and pre-senile cognitive 
decline identified four NP-C cases (17% incidence) [56]. Genetic screening methods have 
been shown able to detect and diagnose NP-C among EOA patients in whom it might 
otherwise be missed during differential diagnosis [56, 68]. A high-throughput gene 
sequencing study using an ataxia gene panel in 204 patients with EOA confirmed diagnosis 
of NP-C in six patients – a 2.9% incidence [20]. The total frequency of NPC1 gene variants 
was 8/192 (4.17%), representing significant enrichment compared with a frequency of 1.6% 
in the control cohort (p = 0.011) [20]. 
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Overall, published evidence showing a raised frequency of NP-C in the clinical EOA 
population indicates that unexplained EOA is a highly relevant clinical niche for the detection 
of new NP-C cases [20, 31, 56]. 
 
3. Movement disorders - dystonia 
Dystonia represents the third most common movement disorder and is acknowledged as one 
of the core neurological manifestations of NP-C, occurring in 40–50% of diagnosed cases 
[13, 59, 63, 69]. In affected patients, dystonia contributes strongly to patient disability [14]. It 
can either be focal, affecting the hands, face or upper limbs, or more generalized, affecting 
gait [10, 69]. Dystonia tends to occur later than other neurological signs during the course of 
NP-C, and has been reported most frequently in the juvenile and adolescent/adult 
neurological onset forms [8, 10, 13, 59]. 
The neuropathological changes underlying dystonia are complex. Dystonia is related to basal 
ganglia dysfunction, and correlates with pathology in the striatum [10, 61, 69]. Along with 
other genetic causes, dystonia associated with NP-C may also be related to cerebellar 
dysfunction [70, 71]. 
Over 42 hereditary disorders with associated neurodegeneration have dystonic symptoms, 
which can be categorized into two groups: monogenetic forms with assigned genetic loci 
(primary dystonias) and complex dystonia (‘dystonia plus') syndromes [72]. 'Dystonia plus' 
syndromes, which include NP-C, Wilson disease, GLUT-1 deficiency and organic acidurias, 
comprise dystonia along with concomitant neurological and systemic features [72, 73]. 
Patients with dystonia plus syndrome, especially those displaying progressive dystonic signs 
and one or more of ataxia, myoclonus, VSGP, dysarthria, dysphagia, cognitive decline, 
psychiatric manifestations, cataplexy or splenomegaly, have an increased likelihood of NP-C 
[32, 60, 61, 63, 74]. Ataxia is a particularly common concomitant neurological sign [5, 31]. A 
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young age at onset (<40 years of age) can help distinguish dystonia related to NP-C from that 
associated with middle-age cervical torticollis. Focal dystonic features typically seen in NP-C 
include hand dystonia with wrist flexion and a forced (subtle) smile during speech due to 
dystonia of the jaw muscles (Iodice R, personal communication). Other visible symptoms 
such as facial grimacing and 'round the houses' sign (i.e., corrective horizontal saccades to 
accomplish upward voluntary pursuit movements) have also been described [75].  
Based on observations from patients visiting specialist/tertiary referral clinics, it is estimated 
that up to 2% of dystonia patients could be diagnosed with NP-C, possibly even more [76]. 
While a 'genetics first' approach is sometimes recommended for diagnosis in cases of 
unexplained dystonia, initial biomarker-based methods can provide more rapid findings 
where underlying inherited metabolic diseases are suspected. 
Dystonia is a commonly encountered yet complex neurological sign in clinical practice. 
Based on evidence to date, it is considered essential to increase awareness of NP-C as a 
possible underlying cause. The clinical dystonia population should be considered as a 
relevant clinical niche for further targeted screening for NP-C. However, the complexity of 
differential diagnosis related to dystonia requires that patient cohorts be clearly defined. 
 
4. Early-onset cognitive decline (EOCD) 
Pre-senile dementia or EOCD presents before the age of 65 years, and is being recognized 
more frequently [29]. Most cases of EOCD are related to Alzheimer disease (AD), but 
inherited neurodegenerative etiologies, including NP-C, are being reported more frequently 
as the underlying causes [29, 42, 77]. 
NP-C shares a number of neuropathological features with AD and other dementias such as 
FTD and Lewy body dementia. Published data indicate a potential link between NPC1/NPC2 
mutations and 'dementia plus' syndromes (i.e., where cognitive impairment is accompanied 
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by other neuropsychiatric and systemic symptoms) [78]. Amyloid beta deposition, 
neurofibrillary tangles (NFTs), and tau-related pathology have also been observed in NP-C 
[79, 80, 81], although it is not known whether these features are intrinsically linked with 
lysosomal trafficking defects, or represent more non-specific signs of neurodegeneration in 
NP-C [82, 83, 84, 85]. Further, published data suggest a possible connection with 
apolipoprotein E4 (Apo E4), the principal cholesterol trafficking apolipoprotein in the brain, 
and a known risk factor associated with AD [86, 87]. 
EOCD is observed during disease progression in almost all patients with adolescent/adult-
onset NP-C [69, 88, 89]. EOCD in adult-onset NP-C often presents with concomitant 
psychiatric signs [7, 10, 19, 57, 69, 74, 88, 90, 91, 92]. As a result, NP-C is sometimes 
misdiagnosed as endogenous psychiatric disease, in particular schizophrenia [93]. EOCD is 
less commonly recognized among patients with childhood-onset NP-C, although intellectual 
developmental disorder, poor school performance and learning disabilities are often reported 
in affected children [7, 8, 13, 30, 57, 94]. 
Patients presenting with EOCD should be assessed for all cognitive domains, behavioral 
features, psychiatric history, and functional impairment [42]. Adults with NP-C may have a 
specific profile of cognitive deficits [89]: early signs of cognitive impairment in NP-C 
comprise reduced executive function, processing speed and verbal memory due to frontal-
subcortical deficits [69, 89]. As the disease progresses, further general cognitive decline and 
gradual loss of abilities to perform daily tasks occur alongside prominent memory and 
behavioral impairments [10, 94, 95, 96]. Appropriate neuropsychological tests with elements 
of staging to disease severity may help to detect NP-C [89]. Trail Making tests A & B and 
verbal fluency tests may prove useful in patients with mild disease. The Mini-Mental Status 
Examination [MMSE], Corsi Block-tapping, Find Similarities, and Clock Drawing Tests are 
appropriate for those with more advanced disease. 
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There are only a few published NP-C screening studies among patients with EOCD. Data 
indicate that concomitant neurological symptoms can help to detect new cases. One genetic 
screening study indicated possible enrichment for NP-C among 250 patients with 'pre-senile 
cognitive decline' (i.e., EOCD) with and without psychiatric symptoms [76]. Another study in 
24 patients with EOCD and degenerative ataxia identified four cases of NP-C (17% 
incidence), which increased to 31% among patients who additionally showed VSGP [56]. 
The NPC-SI takes cognitive impairment into account, and could represent an effective 
screening method for NP-C in EOCD [32, 33, 97]. 
Despite the paucity of data from published screening studies, the clinical EOCD population is 
considered a relevant clinical niche for NP-C. Specific neuropsychological tests as well as the 
NPC-SI are considered applicable for screening among EOCD patients.  
 
5. Frontotemporal dementia (FTD) 
FTD is a leading cause of dementia in patients aged <65 years [98, 99], and shares a number 
of features in common with NP-C at the genetic, clinical and neuropathological levels, 
particularly among adult-onset cases. The behavioral variant of FTD is characterized by 
behavioral or cognitive deficits manifesting as early and progressive changes in personality 
(e.g., impulsivity, poor judgement), impaired language ability, and loss of organizational 
skills [98, 100, 101]. Patients with NP-C also often show a history of developmental 
problems and EOCD, and prominent executive dysfunction is frequently observed, 
particularly among patients with later-onset disease [7, 8, 10]. 
Psychotic symptoms are often reported in both FTD and NP-C [7, 19, 102, 103, 104, 105, 
106, 107], and are associated with disrupted frontotemporal pathways and impaired frontal-
subcortical connectivity [93, 108]. As in NP-C [69, 93, 102, 103, 109], psychosis in adults 
with FTD frequently leads to misdiagnosis with schizophrenia, schizoaffective disorder or 
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bipolar disorder, often many years before a final diagnosis is confirmed [106, 110, 111, 112, 
113].  
Approximately one-third of patients with FTD have a family history or confirmed 
predisposing genetic component [29, 114]. Gene variants that have been linked with early-
onset neurodegenerative processes (i.e., those occurring at <40 years of age) common to both 
FTD and NP-C include C9orf72 [115, 116, 117, 118] and the progranulin gene, PGRN, which 
is associated with TAR DNA-binding rotein-43 (TDP-43)-related changes [29, 119]. Further, 
some forms of FTD can be listed alongside NP-C as tauopathies due to mutations in the 
MAPT tau gene on chromosome 17, and subsequent pathological tau accumulation [120, 121, 
122, 123, 124]. Both NP-C and tau-related forms of FTD can display similar tau isoform 
profiles [123, 125]. 
Differential diagnosis of FTD versus NP-C is most likely to be required in adult patients who 
present with cognitive impairment and prominent executive dysfunction above 30 years of 
age, or in patients who present with major mental illness (e.g., schizophrenia-like symptoms, 
possibly with atypical signs) aged 15–30 years. Characteristic clinical manifestations that 
help distinguish NP-C from FTD and other forms of EOCD include both visceral and 
neurological symptoms [10]. Hepatosplenomegaly in NP-C has been proposed as a 
differential diagnostic indicator versus FTD and other etiologies associated with EOCD, 
although a lack of hepatosplenomegaly should not be taken to exclude NP-C. Abnormal 
saccadic eye movements (including VSGP) also serve as a strong indicator of possible NP-C. 
There are relatively few published data on NP-C gene mutations from clinical screening 
studies in FTD patients. A genetic screening study including 133 FTD patients along with 
other neurodegenerative disorders did not detect any NPC1/NPC2 gene variants [22]. 
Findings from an ongoing genetic screening analysis of NPC1/NPC2 variants in 200 French 
FTD patients are awaited.  
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Despite the lack of supportive data, the degree of symptomatic overlap and emerging 
evidence of genetic and pathophysiological commonalities between NP-C and FTD suggest 
that the clinical FTD population could be a relevant niche for the detection of NP-C. 
 
6. Parkinsonism 
Parkinsonism is clinically defined by tremor, bradykinesia/akinesia, rigidity, and postural 
instability and occurs in numerous sporadic and inherited neurological diseases. It is 
described in a range of tauopathies, and is often associated with EOCD [126]. However, 
parkinsonism can be difficult to discern among other prevailing neurological symptoms that 
are common in NP-C [127]. For instance, some patients may be treated with neuroleptic 
drugs, and subsequently develop iatrogenic parkinsonism. 
A cohort study of movement disorders in adults with NP-C reported mild parkinsonism 
(bradykinesia, axial rigidity, hypomimia or isolated rest tremor) in approximately 10% of 
patients [69]. In this series, it did not represent a key diagnostic feature, and was usually 
detected only after systematic neurological examination [69]. 
Substantial evidence from genetic studies indicates a possible association between impaired 
lysosomal function and parkinsonism. A number of Parkinson disease (PD) genes (including 
SNCA, LRRK2, parkin, PINK1, and ATP13A2) are known to regulate lysosome-dependent 
pathways or lysosomal activity [128, 129, 130], while glucocerebrosidase (GBA1) mutations 
in GD patients and SMPD1 mutations have been associated with PD [131, 132, 133, 134, 
135, 136]. With reference to NP-C, the autophagy-lysosome pathway may be a contributory 
pathophysiological factor for PD [137]. Autopsy evidence from NP-C patients indicated 
aberrant phosphorylation and aggregation of synuclein-alpha protein in Lewy bodies, along 
with typical tau-related neuropathological features [80, 138]. 
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Several reports have suggested potential links between parkinsonism and NPC1/NPC2 
mutations [22, 130, 139]. A case series reported parkinsonism syndrome in a total of four 
patients who had a single heterozygous NPC1 mutation [140]. A separate report of a 
heterozygous NPC1 mutation carrier with PD-like symptoms was also described [141]. 
However, a large-scale genetic screening study in 563 European PD patients identified single 
heterozygous pathological NPC1/NPC2 mutations in only 1.1% [22]. This was not 
significantly higher than in a control group (n = 7/846; 0.8%). No PD patients had 
homozygous NPC1/NPC2 mutations, although 16 variants of unknown significance were 
detected (12 in NPC1 and four in NPC2).  
Overall, current evidence from clinical and genetic studies do not support parkinsonism as an 
important clinical niche for undetected cases of NP-C. More studies are needed to investigate 
whether NPC1/NPC2 mutations might be found in younger patients with parkinsonism. The 
prevalence of NP-C gene variants among other, non-European cohorts has also not yet been 
established. 
 
7. Progressive supranuclear gaze palsy (PSP) 
PSP is a neurodegenerative disease characterized by VSGP, gait disturbance, akinetic-rigid 
syndrome with levodopa unresponsiveness, dementia and premature death [142, 143], and is 
classified clinically as a form of atypical parkinsonism [144]. Clinical cases of NP-C have 
been misdiagnosed as PSP [145, 146]. VSGP combined with cognitive decline is considered 
pathognomonic for NP-C [7, 8, 10, 147, 148, 149]. Voluntary vertical saccades are affected 
first in NP-C, followed by reduced slow eye pursuit movements and impaired horizontal 
saccades, and over time, full-blown VSGP develops due to increasing brainstem 
neurodegeneration [150, 151, 152]. Between 65% and 81% of patients with NP-C have 
impaired saccadic eye movements, which usually start in the late-infantile period [10, 13, 32, 
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57], but it is suspected that these percentages are underestimations due to lack of proper 
evaluation. The early impairment of vertical saccades, often preceding other motor 
symptoms, indicates a delicate sensitivity of the rostral interstitial nucleus of the medial 
longitudinal fasciculus (riMLF) to neurodegenerative decay in NP-C [148, 153]. The 
vulnerability of riMLF neurons to NP-C pathophysiology is not yet fully understood, but 
might offer a good window in the future to study the specific and early pathophysiology 
underlying NP-C neurodegeneration.  
Approximately 40% of cases of PSP are associated with underlying tauopathic changes, and 
in this respect share pathophysiological aspects common to NP-C [142, 154, 155]. Many 
patients also show overlaps in the profile of clinical symptoms, particularly movement 
disorders and cognitive impairments [120, 142, 156]. This can present a challenge in 
differential diagnosis [146]. A key distinguishing factor between the two conditions is age at 
onset; PSP usually starts in the fifth to the seventh decade of life, while NP-C generally 
presents much earlier on. 
The occurrence of NP-C within the clinical PSP population is unknown. A case series in four 
PSP patients reported filipin test results consistent with NP-C, but no genetic confirmation 
was established [58]. A genetic screening study in multiple neurodegenerative diseases, 
including 94 patients with PSP, did not detect any NPC1/NPC2 variants [22]. Given the 
clinical similarities between NP-C and PSP, it is recommended that patients who present with 
PSP-like clinical signs before the ages typically associated with PSP should be tested for NP-
C [157]. More specifically, the presence of cerebellar ataxia, EOCD with onset before 50 
years of age, or visceral symptoms such as splenomegaly can help distinguish between PSP 
and NP-C [10, 66, 144]. Methods for assessing ocular motor abnormalities characteristic of 
PSP are available [158, 159]. Published data suggest that analysis of cerebrospinal fluid 
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(CSF) truncated tau levels may also provide useful information for the differential diagnosis 
[160, 161]. 
No confirmed NP-C cases have been identified through any screening approaches in PSP to 
date. While PSP is considered less relevant as a potential clinical niche for undetected NP-C 
patients, further investigations in PSP are still considered scientifically reasonable. 
 
8. Organic psychosis 
NP-C, along with several other inborn errors of metabolism (IEMS), is among a large number 
of diseases associated with organic psychiatric disturbances [95, 108, 162, 163]. Psychiatric 
symptoms are most commonly observed in adolescent/adult-onset NP-C, and have been 
reported in up to 55% of patients in this category [7, 8, 19, 57, 69, 88, 91]. Notably, 
symptoms are often reported at initial presentation [69, 93]. In a study of 87 NP-C patients 
from the US national NP-C cohort, psychiatric problems were significantly more common 
among patients aged ≥18 years (45%) compared with those aged <18 years (11%; p < 0.01) 
[57]. 
As seen in many diseases associated with organic psychiatric symptoms, NP-C patients who 
initially present in psychiatric practice may remain improperly diagnosed, or go undiagnosed, 
for years due to heterogeneous clinical features, limited awareness of NP-C as a possible 
underlying condition, or the long time frame over which the disease progresses [87]. 
Psychiatric symptoms may therefore be the only manifestation of NP-C for years before other 
symptoms become apparent [93, 164]. Consequently, patients who present to psychiatrists 
often experience significant delay before a definitive diagnosis of NP-C [7, 93, 108, 162].  
Psychotic symptoms are the most frequent psychiatric manifestations reported in NP-C [19, 
35, 47, 52]. and often manifest as schizophrenia-like symptoms comprising paranoid 
delusions, auditory hallucinations, and disorganized thoughts [7, 74, 93, 103, 162, 164]. 
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Depression, bipolar disorder and obsessive-compulsive disorder are also reported [10, 19, 
108, 163]. A retrospective survey of psychiatric presentations among French adult NP-C 
patients who underwent psychiatric evaluation reported psychotic symptoms in 55%, and half 
had a psychiatric diagnosis: schizophrenia in 27% and depression in 23% [19]. A systematic 
literature analysis of psychiatric manifestations in 58 NP-C patients who were mostly 
adolescents or adults at neurological onset reported psychotic symptoms in 62% overall, and 
behavior- and mood-related manifestations in 52% and 38%, respectively [18]. Notably, 87% 
of patients in the US NP-C cohort had learning difficulties, which are often also encountered 
in psychiatric practice [57]. 
There are few published data from genetic screening studies of NP-C in psychiatric patient 
populations. However, the 'ZOOM' study, which systematically screened for NP-C gene 
mutations in 250 patients with neurological and psychiatric symptoms, identified three 
(1.2%) new NP-C cases and 12 (4.8%) more patients who were classified as 'NP-C uncertain' 
[76]. The detection rate in this study was substantially higher than the general population, and 
suggests that screening for NP-C in selected neuropsychiatric populations may result in the 
identification of more new cases. 
Vigilance for atypical psychiatric signs, neurological manifestations, and visceral symptoms 
can aid in the differential diagnosis of NP-C versus primary psychiatric conditions and other 
organic causes [162]. Readily recognizable psychiatric signs that should trigger the suspicion 
of underlying organic disease in patients with schizophrenia-like symptoms include: acute 
confusional states; a preponderance of visual hallucinations over auditory hallucinations; 
catatonia; early or acute onset of psychiatric symptoms; fluctuating symptoms; antipsychotic 
treatment resistance; and sensitivity to low doses of high-potency neuroleptics [7, 95, 103, 
162, 165]. Clinical diagnostic algorithms provide a framework for the detection of hidden 
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NP-C (amongst other IEMs) in psychiatric patient populations [95]. The NPC-SI may also be 
useful as a clinical screening tool in psychiatry [32]. 
Published evidence indicates that organic psychosis is an important clinical niche for NP-C 
screening. Improved awareness among psychiatrists of IEMs as possible causes of psychiatric 
symptoms is key to achieving early detection [91]. 
 
9. Amyotrophic lateral sclerosis (ALS) 
ALS is a late-onset motor neuron disease featuring progressive neurodegeneration and a 
degree of symptomatic overlap with NP-C. Both NP-C and ALS can be associated with 
movement disorders, dysphagia, dysarthria, ophthalmoplegia and cognitive 
impairment/dementia [166, 167]. Between 5 and 10% of ALS cases are inherited in an 
autosomal dominant fashion [168]. The two conditions have a number of pathophysiological 
features in common, including tau-associated neurofibrillary tangles [167] and changes in 
intracellular second messengers [82, 169]. 
Despite clinical and neuropathological features held in common between ALS and NP-C, 
there are few published data indicating any firm clinical links. ALS is most common in 
individuals aged ≥60 years, but also occurs in younger patients [170, 171]. Nevertheless, 
based on the distinct overlap in clinical symptomatology in the two conditions (e.g., mild 
upper-girdle motor impairment with predominant VSGP, gait ataxia, dystonia or psychiatric 
features), it is considered most likely that NP-C would be detected among patients with 
young-onset ALS. In terms of differential diagnosis, electrophysiological testing is a widely 
used method for assessing motor neuron disease specific to ALS [172]. However, 
electrophysiological tests in patients with NP-C generally provide mixed findings [173]. 
Signs of acute denervation are often observed in ALS but are not common in NP-C. 
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Only one report of genetic screening for NP-C in ALS has been published to date. Whole-
exome sequencing using NGS was conducted in two siblings who were suspected to have 
ALS, but were subsequently diagnosed with NP-C [23]. 
Overall, there is a paucity of published data on the occurrence of NP-C in the ALS 
population. Thus, without additional evidence, ALS cannot currently be considered a relevant 
clinical niche for NP-C. 
 
10. Chronic inflammatory CNS disease (e.g., multiple sclerosis) 
Multiple sclerosis (MS) occurs in approximately 180/100,000 in Central Europe and North 
America [174]. Common symptoms, which typically start during early adulthood and follow 
a relapsing or progressive course, include ataxia, optic neuritis, sensory disturbance, 
pyramidal weakness, bladder dysfunction, fatigue, insidious cognitive deterioration, and 
depression/euphoria. 
Patients are routinely diagnosed with MS based on CSF analysis demonstrating intrathecal 
immunoglobulin synthesis, white-matter abnormalities on cerebral MRI, and evidence of 
demyelination [175, 176, 177]. In patients who present with typical clinical signs, the 
differential diagnosis is reasonably limited [175], but in less typical cases a wide range of rare 
causes must be considered.  
There are several overlaps in the clinical symptomatology of NP-C and MS, particularly in 
terms of movement disorders (ataxia) [20, 178], oculomotor disturbances (slow saccades, 
impaired saccadic pursuit and VSGP) [56, 148, 151, 175, 179], and cognitive deficits [180, 
181]. In addition, both NP-C and MS share a number of neuroinflammatory changes. Altered 
CSF neuroinflammatory cytokine marker levels, microglial activation and the release of 
neurotoxic cytokines have been reported in both conditions [182, 183, 184]. These are 
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thought to be central pathogenetic features of MS, while their role in NP-C is not clear at 
present. 
Screening for NP-C in patients with presumed MS is appropriate when cranial MRI findings 
are largely normal (i.e., not fulfilling accepted imaging criteria for MS), as is often the case in 
late-onset NP-C [175, 178, 185]. Similarly, the absence of chronic-inflammatory features 
from CSF analysis, persistent inefficacy of disease-modifying MS treatments, or normal 
visual evoked potentials should initiate further evaluation of potential differential diagnoses 
[173, 175]. 
One case of an adult patient with prominent progressive dementia and multiple non-specific 
neurological signs has been reported as 'adult-onset NP-C mimicking features of MS [186]. 
Neurological symptoms included slight bilateral ataxia in the legs and mild saccadic 
dysmetria, concomitant with behavioral, mood and early-onset cognitive impairments. While 
the patient was initially diagnosed with MS based on clinical findings, CSF analysis, and 
cranial MRI, persistent splenomegaly prompted further investigations that led to a diagnosis 
of NP-C [186]. 
Despite anecdotal evidence there are no robust published data to support MS as a relevant 
clinical niche for detecting NP-C. Further studies are required to develop the understanding 
of potentially overlapping disease mechanisms. 
 
11. Cholestasis and hepatosplenomegaly in early-infantile patients 
The earliest presentation of NP-C during infancy may be with non-immune hydrops and fetal 
ascites or isolated splenomegaly [7, 8, 10, 187]. Infants may be born with prolonged, 
unexplained neonatal jaundice lasting >2 weeks, and acute liver failure [7, 10, 16, 17]. These 
symptoms precede any obvious neurological symptoms in the course of NP-C [6, 7, 8, 10, 
13]. 
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The differential diagnosis of cholestatic symptoms in pediatric patients is extensive [188, 
189, 190, 191, 192, 193], and presents challenges for the identification of NP-C in pediatric 
liver units [194]. However, the vast majority, if not all patients with NP-C will have 
splenomegaly at birth. Pulmonary disease is a rare concomitant complication, but is another 
strong clinical indicator. Portal hypertension needs to be excluded in older children who 
present with cholestatic symptoms [17, 193]. 
NP-C has been reported as one of the most common genetic causes of liver disease during 
infancy [6, 10, 195, 196]. For example, in a UK study of infants investigated for acute liver 
failure, three cases of NP-C (8%) were identified among 37 patients with an IEM [195]. In a 
North American liver unit, NP-C alone accounted for approximately 8% of general pediatric 
patients who were investigated for neonatal cholestasis (n = 40) [196]. 
As visceral symptoms precede neurological symptoms in the course of NP-C, neonates and 
infants who present with visceral symptoms and concomitant neurological signs such as 
developmental delay, hypotonia, and gelastic cataplexy, are clear candidates for additional 
diagnostic testing [6, 10]. An early-onset NPC-SI facilitates the identification of patients with 
suspected NP-C aged ≤4 years of age, based on combinations of some of these key symptoms 
[197]. Patients who exhibit both cholestatic symptoms and splenomegaly show high SI scores 
(indicating strong suspicion of NP-C). 
Genetic screening studies have demonstrated a possible enrichment for NP-C among 
cholestatic infants in the general clinical population. An NGS study with microarray re-
sequencing analysis in 222 infants with cholestasis, acute liver failure, hepatomegaly or 
splenomegaly identified autosomal recessive IEMs in 19 patients (9%), and confirmed NP-C 
in one (0.5%) [198]. Seven (3%) heterozygous individuals with single pathogenic NPC1 
variants were also reported [198]. In a study based on massively parallel sequencing of 93 
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genes associated with inherited cholestatic disorders in infants, a novel pathogenic NPC1 
mutation was identified [24, 199]. 
Overall, data indicate that patients with early cholestasis/prolonged neonatal jaundice or 
hepatosplenomegaly represent a highly relevant clinical niche for the detection of NP-C.  
 
12. Antenatal findings, fetal abnormalities and newborn screening 
Prenatal diagnosis and newborn screening for LSDs have become topics of intense research 
in recent years due to the development of targeted treatment options, improved screening 
methods and the availability of biomarkers [30, 200, 201, 202, 203]. 
In terms of early-infantile clinical symptoms, prolonged neonatal jaundice, splenomegaly 
(with or without hepatomegaly) and fetal ascites (hydrops fetalis) detected during antenatal 
assessment should arouse suspicion of NP-C, even in the absence of a family history [204, 
205]. To date, 15 cases of antenatal-onset NP-C were reported: all featured splenomegaly, 
ascites, hepatomegaly or placentomegaly at a median gestational age of 24 weeks [205]. 
Unexplained fetal hydrops and signs of liver failure may be viewed as additional factors to 
raise suspicion of NP-C [10]. These clinical symptoms are nonspecific, and must be 
considered alongside other causes during differential diagnosis [24, 189, 194, 198]. The 
early-onset NPC-SI is available to support diagnosis based on clinical symptomatology in 
infants aged ≤4 years [32, 197]. 
As NP-C is inherited in an autosomal recessive manner, prenatal diagnosis is available to 
affected families if they wish, for the detection of NP-C among siblings of first cases to be 
diagnosed. Traditionally, filipin staining based on chorionic villus sampling was 
recommended for antenatal diagnosis of NP-C [10, 11, 189]. However, as genetic analysis is 
now routinely used in initial diagnostic workup, causative mutations are usually known in 
index cases, and mutation analysis based on chorionic villus sampling or amniocentesis is the 
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method of choice for antenatal diagnosis. Simple testing for free fetal DNA in maternal blood 
may one day allow prenatal screening in affected families, thus avoiding invasive prenatal 
diagnostic procedures and risk of miscarriage [206]. For previously undiagnosed prenatal-
onset and neonatally presenting cases, it is likely that plasma and dried blood spot (DBS) 
biomarkers will become the preferred method for postnatal diagnosis and newborn screening 
of NP-C, particularly in cases with a strong clinical suspicion of NP-C, where only minor 
blood sample volumes are available [21, 30, 55, 189, 202, 207, 208]. 
For newborn screening, NGS and multi-gene panels will make rapid, wide-ranging genetic 
screening more accessible [21, 24, 198]. However, ethical concerns and legal restrictions may 
preclude genetic newborn screening in some countries [21, 209]. 
Overall, patients with certain fetal abnormalities are considered to be a highly relevant 
clinical niche for NP-C screening, and multi-panel approaches (e.g., with biomarkers) may 
prove especially helpful. While newborn screening offers tangible benefits in terms of early 




In this review, twelve clinical niches considered to have a potential of harboring patients with 
an increased risk of NP-C were examined in detail via the published evidence and expert 
opinion. Niches with strong evidence to support their high relevance to detecting and 
diagnosing NP-C where it has previously been overlooked include: antenatal findings, fetal 
abnormalities and newborn screening, movement disorders (EOA and dystonia), organic 
psychosis, cholestasis and hepatosplenomegaly in early-infantile patients, and patients 
affected by familial aspects and ancestry. Niches thought to be of potential relevance, where 
further data are required or studies are still ongoing include: EOCD, FTD, parkinsonism, and 
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chronic inflammatory CNS disease such as MS. Only relatively weak evidence was available 
to suggest an increased likelihood of detecting NP-C in ALS and PSP niches.  
It is possible that other putative clinical niches may also yield further valuable data (e.g., 
other tauopathies, early-onset AD, multiple system atrophy, Huntington-like disease, 
treatment-resistant epilepsy, patients with one identified NPC1 or NPC2 mutation). Screening 
initiatives within locally existing niche cohorts represent a good starting point for future 
studies. 
Future screening studies in clinical niches identified here as carrying an increased risk of NP-
C would address the following goals: 1) confirm whether NPC1/NPC2 gene mutations 
underlie unclear symptomatology in suspected cases; 2) exclude NP-C in patients where, 
despite unclear symptomatology, it is not present; and 3) aid secondary identification of other 
relevant rare diseases for differential diagnostic purposes. The identification of hidden NP-C 
cases associated with unclear symptoms in at-risk patient groups is important because a 
targeted therapy (miglustat) is available that is of most benefit where treatment is initiated 
early on in the disease course [10, 11, 210]. 
This review of published evidence serves to highlight that, as in most ultra-rare diseases, 
consideration of clinical symptom combinations/co-morbidities relevant to each niche is a 
vital aspect for the detection of NP-C. For instance, throughout all niches where clinical 
neurological or psychiatric manifestations form part of the core symptomatic profile, 
historical cholestatic symptoms or hepatosplenomegaly, or ongoing visceral symptoms, 
whether symptomatic or not, are consistently acknowledged as strong factors in raising 
suspicion of NP-C. The NPC-SI and the early-onset NPC-SI allow a systematic approach to 
initial screening based on clinical symptomatology [32, 197]. Easy-to-apply and readily 
available tests such as oculomotor examinations and cranial MRI can add valuable further 
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information (e.g., in organic psychosis, dystonia, EOCD, and unclear neuroinflammatory 
disease). 
Rapid, convenient and cost-effective biomarker-based methods for NP-C screening and 
diagnosis are increasingly becoming available in specialized laboratories worldwide [21]. 
Numerous studies have demonstrated the utility of plasma oxysterols as a primary diagnostic 
test for NP-C across a number of patient cohorts [21, 25, 26, 211]. Lysosphingolipids have 
also been shown to be effective biomarkers for NP-C [21, 27, 28], additionally providing the 
advantage of adaptation to robust high-throughput setups using DBS filter cards and 
multiplex analysis of NP-C along with other sphingolipidoses (e.g., GD and Fabry disease). It 
is thought likely that combined analysis of both oxysterol and lysosphingolipid profiles will 
help to improve diagnostic specificity for NP-C versus other IEMs. Bile acid assays represent 
a promising additional biomarker option for NP-C screening/diagnosis [21, 29, 30]. While 
limited published data are available, an advantage of lysosphingolipid and bile acid-based 
methods is that they can be conducted in plasma samples or DBS. Studies utilizing some of 
these biomarker methods are ongoing in some clinical niches addressed in this review (e.g., 
in dystonia, PSP, and early-onset cholestasis). 
Improvements in the speed, accuracy, accessibility and cost-effectiveness of NPC1/NPC2 
analysis over the last decade have led to genetic analysis now being considered as the 
primary means of confirming NP-C diagnosis [21]. While Sanger-based cDNA and gDNA 
sequencing remains the mainstay of NP-C genetic analysis, NGS techniques, which can be 
adapted to gene panels and used in whole-exome and whole-genome sequencing, are 
increasingly being applied [21]. However, due to certain error rates inherent in all genetic 
approaches, complementary testing by MLPA and quantitative PCR can provide further proof 
[21, 76]. Data from studies utilizing NGS in certain NP-C clinical niches covered in this 
review have already been published (e.g., in EOA, ALS and early-onset cholestasis) [20, 23, 
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24]. Further data on the application of these techniques in prenatal testing and newborn 
screening/diagnosis are awaited [21]. 
 
Conclusions 
Several clinical niches have been identified that harbor patients at increased risk of NP-C. 
There is a continued need for improved awareness of NP-C as a possible underlying cause of 
symptoms commonly encountered in these niches. Increased vigilance for combinations of 
characteristic clinical disease manifestations, along with the inclusion of NP-C in biomarker 
and genetic screening assays, could reduce diagnostic delays and result in earlier initiation of 
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